Logo

Cancer Genetics Complete::IO Immuno-Oncology Panel

Jan 17, 2018

Cancer Genetics has expanded its immuno-oncology panel, Complete::IO, to include five new markers, bringing the total to 27. The test is a multi-marker panel for characterization of the immune repertoire of cancer patients, including circulating immune cell populations and the tumor microenvironment.

The assay is designed to help identify patients who are likely to respond to specific therapies, as well as to monitor and stratify patient populations during clinical trials. The five new markers now allow the test to detect myeloid-derived suppressor cells, as well as those that express PD-1, PD-L1, or PD-L2.

Breaking News
The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.